Skip to product information
1 of 1

Ambossle

European Association of Dermato-Oncology 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024

European Association of Dermato-Oncology 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024

Regular price $60.00 USD
Regular price $65.00 USD Sale price $60.00 USD
Sale Sold out

we'll contact you for payment after receiving your order

European Association of Dermato-Oncology 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024

Include: 26 videos + 1 pdf, size: 21.1 GB

 Target Audience: dermatologists, oncologists, pathologists

 Information:

The 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024 is an interdisciplinary global conference focused on the latest advancements in melanoma and skin cancer. It will take place on June 27–28, 2024, at the Hilton Hotel Munich Park, Germany.

Key Details:

  • Format: Hybrid (In-person & Virtual)
  • Congress Presidents: Axel Hauschild (Kiel, Germany) & Claus Garbe (Tuebingen, Germany)
  • Topics Covered:
    • Results and interpretations of ASCO 2024 presentations
    • Adverse event management for targeted and immunotherapies
    • Gut microbiome and its role in immuno-oncology
    • Bispecific T-cell engagers (BTE) in cutaneous and uveal melanomas
    • Neoadjuvant vs. perioperative immune checkpoint inhibitors (ICI)
    • Cutaneous T-cell lymphoma (CTCL)
    • Adjuvant treatment of melanoma
    • Interactive case discussions on complex melanoma and non-melanoma cases

This meeting provides a comprehensive overview of new developments in melanoma diagnostics, drug development, and clinical trials, fostering interaction between clinicians, researchers, and industry experts

The 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024 is designed for medical professionals specializing in melanoma and skin cancer treatment. The target audience includes:

  • Dermatologists and oncologists focused on melanoma and skin cancer.
  • Clinical researchers involved in melanoma diagnostics and therapy.
  • Pathologists specializing in skin cancer histopathology.
  • Medical professionals interested in immuno-oncology and targeted therapies.
  • Industry experts working on drug development and clinical trials.

This interdisciplinary conference provides a comprehensive overview of the latest advancements in melanoma diagnostics, treatment strategies, and emerging therapies. It fosters direct communication between clinicians, researchers, and industry representatives

 

Topics:

  • 16_EPCM-2024_FINAL-Program_web.pdf
    CLOSING REMARKS.mp4
    KEYNOTE LECTURE I.mp4
    KEYNOTE LECTURE II.mp4
    KEYNOTE LECTURE III.mp4
    KEYNOTE LECTURE IV.mp4
    OPENING OF THE CONFERENCE.mp4
    PARALLEL SYMPOSIUM I Adverse event management of targeted and immunotherapies.mp4
    PARALLEL SYMPOSIUM II Real world evidence studies from registries.mp4
    PARALLEL SYMPOSIUM III Cutaneous T-cell lymphoma (CTCL).mp4
    PARALLEL SYMPOSIUM IV Interactive Discussion of complex melanoma cases.mp4
    PARALLEL SYMPOSIUM V Interactive Discussion of complex non-melanoma cases.mp4
    PARALLEL SYMPOSIUM VI Innovative therapies for orphan diseases.mp4
    SATELLITE SYMPOSIUM I NOVARTIS Gold Sponsor Yesterday, Today & Tomorrow Long-Term Benefits with Targeted Therapy in Adjuvant Melanoma.mp4
    SATELLITE SYMPOSIUM II BMS Gold Sponsor IO-Combinations in Melanoma- How to Proceed – Less or More.mp4
    SATELLITE SYMPOSIUM III MSD Platinum Sponsor Advancements in Early Melanoma Integrating Recent Updates into Clinical Practice.mp4
    SATELLITE SYMPOSIUM V REGENERON Platinum Sponsor Evolving Perspectives on Treatment Roadmap for Advanced Non-melanoma Skin Cancer.mp4
    SATELLITE SYMPOSIUM VI PHILOGEN Sponsor Novel treatments for locally advanced skin cancers.mp4
    SATELLITE SYMPOSIUM VII MERCK Bronze Sponsor Leveraging Real-World Evidence in Advanced Merkel Cell Carcinoma- Insights from Clinical Practice.mp4
    SYMPOSIUM I My personal highlights at ASCO 2024.mp4
    SYMPOSIUM II Which vaccines work and which not.mp4
    SYMPOSIUM III The role of gut microbiome for immunooncology.mp4
    SYMPOSIUM IV Bispecific T-cell engagers (BTE) in cutaneous and uveal melanomas (unrestricted Educational Grant Immunocore).mp4
    SYMPOSIUM V Controversy- Is neoadjuvant or perioperative ICI already standard of care.mp4
    SYMPOSIUM VI Adjuvant treatment of melanoma.mp4
    SYMPOSIUM VII Intralesional therapies for melanoma and NMSC.mp4
    SYMPOSIUM VIII What’s new in NMSC Publication highlights from the last 12 months.mp4
View full details